These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29066217)

  • 1. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
    Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
    Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
    Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
    See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
    Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
    Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
    Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
    Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
    Epstein L; See I; Edwards JR; Magill SS; Thompson ND
    Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
    Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
    JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
    Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH;
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28234. PubMed ID: 32386095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014.
    See I; Soe MM; Epstein L; Edwards JR; Magill SS; Thompson ND
    Am J Infect Control; 2017 Mar; 45(3):321-323. PubMed ID: 27856070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
    Balian C; Garcia M; Ward J
    J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central line-associated bloodstream infections in neonates with gastrointestinal conditions: developing a candidate definition for mucosal barrier injury bloodstream infections.
    Coffin SE; Klieger SB; Duggan C; Huskins WC; Milstone AM; Potter-Bynoe G; Raphael B; Sandora TJ; Song X; Zerr DM; Lee GM;
    Infect Control Hosp Epidemiol; 2014 Nov; 35(11):1391-9. PubMed ID: 25333434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
    Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
    Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings.
    Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
    van den Bosch CH; Frakking FNJ; Loeffen YGT; van Tinteren H; van der Steeg AFW; Wijnen MHWA; van de Wetering MD; van der Bruggen JT
    Eur J Haematol; 2024 May; 112(5):832-839. PubMed ID: 38294085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical practical approach to the surveillance definition of central line-associated bloodstream infection in cancer patients with mucosal barrier injury.
    Chaftari AM; Jordan M; Hachem R; Al Hamal Z; Jiang Y; Yousif A; Garoge K; Deshmukh P; Raad I
    Am J Infect Control; 2016 Aug; 44(8):931-4. PubMed ID: 27112370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of enterococcal central line-associated bloodstream infections in patients with cancer.
    Awadh H; Chaftari AM; Khalil M; Fares J; Jiang Y; Deeba R; Ali S; Hachem R; Raad II
    BMC Infect Dis; 2021 Jul; 21(1):643. PubMed ID: 34225651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of central line bundles on the timing of catheter-associated bloodstream infections and their microbiological distribution in critically ill children.
    Devrim İ; Sandal OS; Çelebi MY; Hepduman P; Gönüllü A; Atakul G; Kara AA; Oruç Y; Gülfidan G; Bayram N; Ağın H
    Eur J Pediatr; 2023 Oct; 182(10):4625-4632. PubMed ID: 37555974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between parenteral nutrition-containing intravenous lipid emulsion and bloodstream infections in patients with single-lumen central venous access: A secondary analysis of a randomized trial.
    Gavin NC; Larsen E; Runnegar N; Mihala G; Keogh S; McMillan D; Ray-Barruel G; Rickard CM
    JPEN J Parenter Enteral Nutr; 2023 Aug; 47(6):783-795. PubMed ID: 37288612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-Year Hospital-Wide Surveillance of Central Line-Associated Bloodstream Infections in a Korean Hospital.
    Seo HK; Hwang JH; Shin MJ; Kim SY; Song KH; Kim ES; Kim HB
    J Korean Med Sci; 2018 Nov; 33(45):e280. PubMed ID: 30402047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Central Line-Associated Bloodstream Infection Rates Among Children With Immune Compromised Conditions: An 11-Year Review.
    Linder LA; Gerdy C; Jo Y; Wilson A
    J Pediatr Oncol Nurs; 2018; 35(6):382-391. PubMed ID: 29665727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.